Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

Andrew Kuykendall, MD, reviews data from TRANSFORM-1 on navitoclax plus ruxolitinib for untreated myelofibrosis, highlighting consistent response rates, no significant symptom improvement with the combination, and challenges managing thrombocytopenia caused by navitoclax, despite its activity and potential as a second-line treatment option.

EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF

EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

Now Viewing

EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

EP: 7.Future Directions in Combination Therapies for Myelofibrosis

EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF

EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis

EP: 12.Emerging Treatments for Myelofibrosis

Related Videos

Related Content

Advertisement

December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT

Related Content

Advertisement

December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT